Intravenous Immunoglobulin Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

IVIG is a market for the intravenous infusion of immune globulins. The market is expected to reach a size of USD 12.39 billion by 2024, and is forecast to reach USD 19.0 billion by 2035. The CAGR (compound annual growth rate) of this market is 3.99% between 2025 and 2035. The growing occurrence of immune deficiency disorders and the growing geriatric population are driving the market. The development of new formulations and the improvements in manufacturing processes are also contributing to the market. The leading companies in the IVIG market, including Grifols, CSL Behring, and Takeda, are strengthening their positions in the market by introducing new products and improving their distribution networks. These companies are collaborating with each other to develop new IVIG products that can be used for the treatment of various immune deficiencies. Such efforts not only enhance the products but also help the IVIG market to become more competitive.

Regional Market Size

Regional Deep Dive

OVERVIEW The Intravenous Immunoglobulin (IVIG) market is characterized by high growth potential across all regions, which is mainly driven by increasing prevalence of immune deficiency disorders, technological advancements, and rising awareness of the benefits of IVIG. Each region is characterized by unique market dynamics, which are influenced by the availability of healthcare facilities, regulatory frameworks, and the population. In North America and Europe, the demand for IVIG is high, owing to the availability of established health care systems, while Asia-Pacific is characterized by high growth potential, owing to the increasing penetration of IVIG and the rising patient population.

Europe

• The European Medicines Agency (EMA) has introduced new guidelines aimed at improving the safety and efficacy of IVIG therapies, which is expected to enhance patient trust and increase adoption rates across member states.
• Recent collaborations between pharmaceutical companies and research institutions in Europe are focusing on developing next-generation IVIG products, which could lead to more effective treatments and broaden the therapeutic applications of IVIG.

Asia Pacific

• Countries like Japan and China are witnessing a surge in IVIG usage due to rising incidences of autoimmune diseases and a growing elderly population, prompting local governments to invest in healthcare infrastructure and IVIG accessibility.
• Innovative distribution models, including partnerships with local healthcare providers, are being implemented by companies like Takeda to enhance the reach of IVIG therapies in rural and underserved areas.

Latin America

• Regulatory bodies in Brazil and Mexico are working to harmonize IVIG regulations with international standards, which is anticipated to facilitate smoother market entry for new products and improve patient access.
• Pharmaceutical companies are increasingly focusing on educational campaigns to raise awareness about the benefits of IVIG therapy among healthcare professionals and patients, which is expected to drive demand in the region.

North America

• The U.S. Food and Drug Administration (FDA) has shortened the approval process for IVIg products, thus encouraging innovation and faster market penetration of new products. This is expected to lead to increased competition and availability of IVIg treatments.
• Key players such as Grifols and CSL Behring are investing heavily in expanding their production capacities in North America, responding to the increasing demand for IVIG, particularly for treating chronic conditions like primary immunodeficiency.

Middle East And Africa

• In low-income countries, the World Health Organization has launched access-to-immunoglobulins programmes, which will significantly increase the availability of IVIg for patients with immune deficiency.
• Local manufacturers in countries like South Africa are beginning to produce IVIG, supported by government incentives aimed at boosting domestic production and reducing reliance on imports.

Did You Know?

“Did you know that IVIG is derived from the pooled plasma of thousands of donors, making it a unique therapy that not only provides antibodies but also contains a variety of immunomodulatory factors?” — American Association of Blood Banks (AABB)

Segmental Market Size

The Intravenous Immunoglobulin market is currently growing steadily. This growth is mainly due to the rising number of autoimmune diseases and immune deficiencies. Awareness of IVIG among patients and physicians is also on the rise, as are supportive regulations that facilitate the faster approval of new indications. Also, the availability of IVIG is improving and the cost of production is falling, which further stimulates the market. This is a mature market. The leading companies in the field are Grifols and Takeda. The main indications are for the treatment of Guillain-Barre syndrome and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The pandemic of COVID19, which has sharpened the focus on immunotherapy, and government mandates to increase the use of biologicals, are also stimulating growth. Product development is also being influenced by new production methods, such as recombinant DNA technology and improved purification processes, which are designed to ensure greater efficacy and safety.

Future Outlook

From 2024 to 2035 the market for intravenous immune globulin is forecast to increase from $13,392 million to $19 billion, at a compound annual growth rate (CAGR) of 3.96%. The growing number of autoimmune disorders, primary immune deficiencies and neurodegenerative disorders will drive the demand for IVIg. The penetration of IVIg into the target population is expected to increase by 2035 from the current 10 to 12 percent to 15 to 20 percent. Technological innovations such as the development of subcutaneous immune globulin and improved purification processes are expected to further increase the effectiveness and safety of IVIg, and thus stimulate market growth. In addition, supportive regulatory and reimbursement policies are expected to increase access to IVIg treatments, especially in emerging markets. The growing importance of precision medicine and the integration of digital health solutions will also have a crucial influence on the IVIG market, ensuring that therapies are tailored to the individual needs of patients. The IVIG market is expected to change significantly over the next 20 years, driven by a combination of factors such as a growing patient population, technological innovations and the development of new therapies.